Wedmont Private Capital’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.17M Buy
5,938
+2,116
+55% +$228K 0.03% 343
2026
Q2
$261K Sell
3,822
-727
-16% -$37.6K 0.01% 801
2026
Q1
$237K Buy
+4,549
New +$212K 0.01% 748
2024
Q3
– Sell
-3,075
Closed -$373K – 685
2024
Q2
$373K Buy
3,075
+1,003
+48% +$127K 0.02% 422
2024
Q1
$231K Buy
+2,072
New +$209K 0.02% 524
2023
Q2
– Sell
-2,087
Closed -$334K – 513
2023
Q1
$334K Sell
2,087
-1,428
-41% -$236K 0.04% 309
2022
Q4
$634K Buy
+3,515
New +$575K 0.09% 162
2022
Q3
– Sell
-2,110
Closed -$301K – 394
2022
Q2
$301K Sell
2,110
-1,237
-37% -$177K 0.06% 234
2022
Q1
$577K Buy
3,347
+1,276
+62% +$215K 0.13% 126
2021
Q4
$435K Buy
+2,071
New +$606K 0.13% 123

Other funds holding MRNA

Wedmont Private Capital's MRNA Position: Q3 2026 in Review

Wedmont Private Capital increased its Moderna (MRNA) stake by 55% in Q3 2026, buying an estimated $228K and bringing the position to 5,938 shares worth $1.17M. The position accounts for 0.03% of the portfolio, ranked #343.

Wedmont Private Capital first reported a position in MRNA in Q4 2021 and has held it in 10 quarters since. 32 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Wedmont Private Capital held 5,938 shares of Moderna worth $1.17M as of Q3 2026.
  • Wedmont Private Capital bought 2,116 Moderna shares in Q3 2026, an estimated $228K.
  • Moderna made up 0.03% of Wedmont Private Capital's portfolio in Q3 2026, its #343 holding.
  • Wedmont Private Capital first reported a position in Moderna in Q4 2021 and has held it in 10 quarters since.
  • 32 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Wedmont Private Capital's 13F filing for Q3 2026, filed 9 Oct 2026.